Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NYSE:GSK NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$97.88+1.2%$108.55$81.20▼$131.49$23.26B1.391.11 million shs1.41 million shsGSKGSK$40.31-1.3%$38.78$31.72▼$43.62$83.16B0.533.64 million shs2.79 million shsJNJJohnson & Johnson$177.49-0.3%$171.25$140.68▼$181.16$428.83B0.47.44 million shs4.77 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-13.98%-14.78%-9.02%-21.60%GSKGSK0.00%+0.99%+3.84%+0.77%-5.12%JNJJohnson & Johnson0.00%-0.05%+0.76%+14.72%+7.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$97.88+1.2%$108.55$81.20▼$131.49$23.26B1.391.11 million shs1.41 million shsGSKGSK$40.31-1.3%$38.78$31.72▼$43.62$83.16B0.533.64 million shs2.79 million shsJNJJohnson & Johnson$177.49-0.3%$171.25$140.68▼$181.16$428.83B0.47.44 million shs4.77 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%-13.98%-14.78%-9.02%-21.60%GSKGSK0.00%+0.99%+3.84%+0.77%-5.12%JNJJohnson & Johnson0.00%-0.05%+0.76%+14.72%+7.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.76Moderate Buy$135.8038.74% UpsideGSKGSK 1.86Reduce$37.38-7.28% DownsideJNJJohnson & Johnson 2.65Moderate Buy$176.29-0.68% DownsideCurrent Analyst Ratings BreakdownLatest JNJ, BNTX, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$136.008/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/14/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$138.00 ➝ $136.008/5/2025BNTXBioNTechBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$126.00 ➝ $134.008/5/2025BNTXBioNTechWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$170.00 ➝ $150.007/23/2025JNJJohnson & JohnsonErste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy7/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$180.00 ➝ $190.007/17/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$164.00 ➝ $167.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B7.90N/AN/A$87.61 per share1.12GSKGSK$31.63B2.60$5.51 per share7.32$8.07 per share5.00JNJJohnson & Johnson$88.82B4.81$13.08 per share13.57$29.69 per share5.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)GSKGSK$3.29B$2.1618.668.672.0410.81%49.22%11.31%10/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3518.9816.032.2725.00%32.49%13.00%10/14/2025 (Estimated)Latest JNJ, BNTX, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025BNTXBioNTech-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 million7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AGSKGSK$1.684.17%N/A77.78%N/AJNJJohnson & Johnson$5.202.93%N/A55.61%64 YearsLatest JNJ, BNTX, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.618.48GSKGSK1.070.870.57JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%GSKGSK15.74%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%GSKGSK10.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.40 million194.24 millionOptionableGSKGSK68,6292.04 billion1.83 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ, BNTX, and GSK HeadlinesRecent News About These CompaniesJohnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Julie Johnson1 hour ago | marketbeat.com3 Dividend Growers That Fly Under the Radar (JNJ)...September 15 at 5:45 PM | marketbeat.comRep. Kelly Morrison Sells Off Shares of Johnson & Johnson (NYSE:JNJ)September 15 at 2:05 PM | marketbeat.comJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual MeetingSeptember 15 at 8:00 AM | prnewswire.comDavis Investment Partners LLC Acquires 17,089 Shares of Johnson & Johnson $JNJSeptember 15 at 7:04 AM | marketbeat.comJohnson & Johnson $JNJ Shares Bought by Avity Investment Management Inc.September 15 at 7:02 AM | marketbeat.comAtwood & Palmer Inc. Increases Holdings in Johnson & Johnson $JNJSeptember 15 at 6:45 AM | marketbeat.comMartin Capital Partners LLC Boosts Stake in Johnson & Johnson $JNJSeptember 15 at 6:36 AM | marketbeat.comWebster Bank N. A. Decreases Stake in Johnson & Johnson $JNJSeptember 15 at 6:28 AM | marketbeat.comCanandaigua National Bank & Trust Co. Has $14.62 Million Position in Johnson & Johnson $JNJSeptember 15 at 6:16 AM | marketbeat.comNBC Securities Inc. Sells 1,893 Shares of Johnson & Johnson $JNJSeptember 15 at 5:57 AM | marketbeat.comIf You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have TodaySeptember 15 at 5:50 AM | fool.comQuintet Private Bank Europe S.A. Sells 3,650 Shares of Johnson & Johnson $JNJSeptember 15 at 5:31 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Gradient Investments LLCSeptember 15 at 5:30 AM | marketbeat.comAdams Asset Advisors LLC Trims Stock Position in Johnson & Johnson $JNJSeptember 15 at 5:30 AM | marketbeat.comE. Ohman J or Asset Management AB Reduces Stock Position in Johnson & Johnson $JNJSeptember 15 at 5:30 AM | marketbeat.comIf You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have TodaySeptember 15 at 5:19 AM | fool.comParallel Advisors LLC Decreases Position in Johnson & Johnson $JNJSeptember 15 at 5:05 AM | marketbeat.comJohnson & Johnson $JNJ Stock Holdings Lifted by Wealth Alliance Advisory Group LLCSeptember 15 at 5:03 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Stock Rating Upgraded by Wall Street ZenSeptember 15 at 3:13 AM | americanbankingnews.comSage Capital Advisors llc Buys 1,650 Shares of Johnson & Johnson $JNJSeptember 14 at 7:09 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025JNJ, BNTX, and GSK Company DescriptionsBioNTech NASDAQ:BNTX$97.88 +1.14 (+1.18%) Closing price 04:00 PM EasternExtended Trading$97.55 -0.33 (-0.34%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.GSK NYSE:GSK$40.31 -0.52 (-1.27%) Closing price 03:59 PM EasternExtended Trading$40.38 +0.06 (+0.16%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Johnson & Johnson NYSE:JNJ$177.49 -0.57 (-0.32%) Closing price 03:59 PM EasternExtended Trading$177.50 +0.01 (+0.01%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
